GENinCode

GENinCode is a U.K. limited company specializing in risk assessment and prediction of cardiovascular disease. Cardiovascular disease (CVD) is a broad disease classification which includes coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension, venous thromboembolism and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States.

GENinCode products provide genetic information to enable patients and healthcare practitioners to assess and predict the onset of cardiovascular disease. Our tests and reports help inform health care practitioners and patients of their health risk enabling behavioral and lifestyle changes alongside delivering the most effective treatment pathways.

GENinCode U.K. Limited was incorporated in September 2018 and subsequently acquired the products, assets and know-how of the Ferrer inCode and the Gendiag.exe businesses, then part of Ferrer, a large pharmaceutical and healthcare company based in Spain. GEN inCode has a strong, granted intellectual property portfolio with a vision to educate patients on cardiovascular risk assessment using the predictive capability of GEN inCode products and lifestyle choices to help improve patient outcomes.

GENinCode has amassed significant investment over the past 15 years in its research and development of predictive and preventative technology to cardiovascular disease.

GENinCode has developed a proprietary online cloud-based system Sitab® to integrate patients clinical and genetic data and provide online reporting capabilities to health care practitioners.

The Core Products of GEN inCode Include:

Cardio inCode® - Score and Check® - Coronary predictive/risk assessment.

Thrombo inCode® - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment.

Lipid inCode® - Familial Hypercholesterolemia Diagnosis and risk stratification.

SudD inCode® - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.

GENinCode operates business units in Europe and the United States in the following locations:

GENinCode UK Limited
One, St. Peters Square,
Manchester, United Kingdom, M2 3DE

GENinCode S.L.U.
Rambla Egara, 235 Terrassa ES-08224
Diagonal, 622 Barcelona ES-08021

GENinCode U.S. Inc.
Corporation Trust Center
1209 Orange St, Wilmington, DE 19801 U.S.

Directors

Matthew Walls – Chief Executive Officer

Matthew Walls – Chief Executive Officer

As Chief Executive Officer, Matthew leads GENinCode’s vision to accelerate the healthcare industry shift to Predictive Genetics to deliver patient-focused, value-based care to improve the treatment and management of cardiovascular disease. Matthew brings more than 30 years of senior leadership experience in leading, advising and developing public and private health care technology companies. Matthew has previously served as CEO for several UK public limited companies and private equity-based groups starting his career with ICI Plc and helping to lead its transition to AstraZeneca Plc. Matthew is a chartered accountant by background.

Jordi Puig – Chief Operations Officer

Jordi Puig – Chief Operations Officer

Jordi is the Chief Operating Officer for the Group and formerly a co-founder and CEO of Ferrer inCode and co-founder and CFO of Gendiag.exe (part of the Ferrer Group) which was acquired as part of the foundation of GENinCode in September 2018.  Jordi brings more than 15 years experience in pharmaceuticals, biotech and global strategic alliances and finance.

Paul Foulger – Chief Financial Officer

Paul Foulger – Chief Financial Officer

Paul is a qualified certified accountant and an experienced and highly motivated hands-on Chief Financial Officer with a proven, demonstrable track record in the Biotech industry for both AIM listed and private companies. A strategic and commercially focussed leader with a breadth of experience at Board level across large and small companies, specific focus in recent years of pharmaceutical and diagnostic companies in the small to mid-cap space.

Bill Rhodes – Non-Executive Chairman

Bill Rhodes – Non-Executive Chairman

Bill is a Chairman with a proven, demonstrable international track record in the Life Sciences and Diagnostics industry across NASDAQ, Euronext and AIM-listed public companies, as well as private companies in the U.S., UK and Europe. He is a strategic and commercially focused leader with significant experience at the board level across large and small companies, with specific focus in recent years on diagnostic companies in the small to midcap space.

David Evans – Non-Executive Director

David Evans – Non-Executive Director

David is focussed in early stage and high-growth medical diagnostics and life science companies where he has a substantial track record in taking companies through the IPO process and delivering value to shareholders in the public phase of a company. Most recently achieved successful exits for Sirigen, Onyx Scientific, BBI, and Scipac as well as creating substantial uplifts in value for Epistem, DxS, IDS and Scancell.

Sergio Olivero – Non-Executive Director

Sergio Olivero – Non-Executive Director

Sergio is a veteran in the life sciences/healthcare industry with more than 30 years’ experience in diagnostics in Spain and Portugal leading his own company with a highly successful track record of medical device provision to the IVF market.

Andrew Symmonds – Non-Executive Director

Andrew Symmonds – Non-Executive Director

Andrew qualified with PricewaterhouseCoopers as a Chartered Accountant in 1996, having graduated from Surrey University with a Mathematics and Economics (Joint Hons) degree in 1992. Andrew is responsible for both new investments and supporting portfolio companies across the Midlands and the South of England, including generating and protecting shareholder value, exit planning and monitoring performance.

Jeremy Curnock Cook – Non-Executive Director

Jeremy Curnock Cook – Non-Executive Director

Jeremy is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialisation of healthcare innovations and helping entrepreneurs build their international businesses over the past 40 years.

Investors

Following the initial investment in September 2018 by the Board of GENinCode and Santi 1990 S.L., the GENinCode Group has grown rapidly and is now setting up operations in the US.

At the beginning of 2020 the Company raised a private investment round for £400k and in July 2020 Maven Capital Partners and Downing Investment Trust made a £3.0m foundation investment in GENinCode.

Maven Capital Partners is an independent alternative asset manager, with over £660 million of assets under management and available to invest. Maven was formed in 2009 after a buyout of the Aberdeen Asset Management private equity business, and operates from a nationwide network of regional offices.

Over 25,000 investors trust Downing with over £1 billion of their assets, invested into businesses that make a difference, including renewable energy, care homes, health clubs and children’s nurseries.

Contact us: info@genincode.com

Subscribe to our Newsletter


    GENinCode shall respond to requests for information, products and / or services and registration to events, as well as send commercial and legal communications deemed appropriate to the client. You may exercise your rights of access, rectification, cancellation, destruction or, opposition, or limit the treatment of data transfer at any time by notifying GENinCode - For further information please view our privacy policy here.